Meeting
2023 ASCO Annual Meeting
Association between duration of immunotherapy and overall survival in advanced non–small-cell lung cancer.
Authors
Lova Sun
University of Pennsylvania, Philadelphia, PA
Lova Sun , Benjamin Aaron Bleiberg , Wei-Ting Hwang , Melina Elpi Marmarelis , Corey J. Langer , Aditi Puri Singh , Roger B. Cohen , Ronac Mamtani , Charu Aggarwal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9101)
DOI
10.1200/JCO.2023.41.16_suppl.9101
Abstract #
9101
Poster Bd #
89
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Association between immune-related adverse events and microbiome composition in patients with advanced non–small cell lung cancer treated with immunotherapy.
First Author: Marion Tonneau
Poster
2020 ASCO Virtual Scientific Program
Physiologic colonic uptake of 18F-FDG on PET/CT predicts immunotherapy response and gut microbiome diversity in patients with advanced non-small cell lung cancer (NSCLC).
First Author: Lena Cvetkovic
Poster
2020 ASCO Virtual Scientific Program
Real-world performance of blood-based host immune profiling in first-line immunotherapy treatment in advanced-stage non-small cell lung cancer.
First Author: R. Brian Mitchell
Poster
2020 ASCO Virtual Scientific Program
Gut microbiome to predict efficacy and immune-related toxicities in patients with advanced non-small cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.
First Author: Taiki Hakozaki